1. Home
  2. SW vs INSM Comparison

SW vs INSM Comparison

Compare SW & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smurfit WestRock plc Ordinary Shares

SW

Smurfit WestRock plc Ordinary Shares

SELL

Current Price

$41.45

Market Cap

22.6B

Sector

N/A

ML Signal

SELL

Logo Insmed Incorporated

INSM

Insmed Incorporated

SELL

Current Price

$96.79

Market Cap

22.4B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SW
INSM
Founded
1934
1988
Country
Ireland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.6B
22.4B
IPO Year
2024
2000

Fundamental Metrics

Financial Performance
Metric
SW
INSM
Price
$41.45
$96.79
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
17
24
Target Price
$56.53
★ $198.45
AVG Volume (30 Days)
★ 3.9M
2.4M
Earning Date
10-28-2026
10-29-2026
Dividend Yield
★ 4.41%
N/A
EPS Growth
★ 62.20
N/A
EPS
★ 0.29
N/A
Revenue
★ $31,179,000,000.00
N/A
Revenue This Year
$3.10
$197.09
Revenue Next Year
$6.30
$59.16
P/E Ratio
$141.57
★ N/A
Revenue Growth
★ 47.70
N/A
52 Week Low
$32.73
$90.39
52 Week High
$52.65
$212.75

Technical Indicators

Market Signals
Indicator
SW
INSM
Relative Strength Index (RSI) 32.90 27.03
Support Level $40.99 $90.39
Resistance Level $43.13 $119.54
Average True Range (ATR) 1.02 4.26
MACD -0.25 -1.72
Stochastic Oscillator 13.12 3.34

Price Performance

Historical Comparison
SW
INSM

About SW Smurfit WestRock plc Ordinary Shares

Smurfit WestRock PLC manufactures corrugated packaging and consumer packaging, such as folding cartons and paperboard. operates a vertically integrated system supplying wood and recovered fiber to produce various grades of board, which are then converted into packaging products. Its main packaging categories include corrugated containers and consumer packaging, with additional products such as solidboard, kraft paper, graphic board, paper sacks, and bag-in-box packaging. The company's geographical segments include North America (including the U.S., Canada and Mexico), Europe, the Middle East and Africa and Asia-Pacific, and Latin America. The majority of the company's revenue is derived from product sales in the North American region.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: